In March, members of the CTF staff were treated to a talk by Synodos for NF1 Principal Investigator Jill Weimer, PhD, of the Sanford School of Medicine. Dr. Weimer discussed the swine model program currently underway, which we hope will lead to a more accurate screening of drugs to treat NF1. Click thru for a transcript of her talk.
Neurofibromatosis (NF) knows no boundaries, and while the Children’s Tumor Foundation (CTF) is based in the United States, its work is global, funding and collaborating with the best researchers on the planet working on NF. In that spirit, we highly applaud the efforts of the Innovative Medicines Initiative (IMI). The IMI, based in Brussels - Belgium, is a public private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations that facilitates research collaboration in order to advance the development of medical treatments.
Earlier this month, more than 70 researchers, clinicians, patients, staff, and other experts gathered in Palm Beach, Florida for the first Synodos Network Meeting, hosted by the Children’s Tumor Foundation.
The Children’s Tumor Foundation (CTF) and the scientific journal PLOS ONE are collaborating on a new funding program in the area of neurofibromatosis (NF) research. The new initiative, called the Drug Discovery Initiative Registered Report (DDIRR) 2017 Awards, is a funder-publisher partnership to integrate the Registered Reports model in the grant application process.
SpringWorks Therapeutics, a Pfizer-conceived, mission-driven medicines company dedicated to developing innovative potential new treatments for underserved patient communities, launched today with news of promising investigational therapies, including one for neurofibromatosis. The Children’s Tumor Foundation is collaborating with this new company to connect the NF community with these much-needed therapies.